Bhadra Arup K, Altman Roy, Dasa Vinod, Myrick Karen, Rosen Jeffrey, Vad Vijay, Vitanzo Peter, Bruno Michelle, Kleiner Hillary, Just Caryn
1 Northeast Orthopedics and Sports Medicine, Airmont, NY, USA.
2 Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA.
Cartilage. 2017 Jul;8(3):234-254. doi: 10.1177/1947603516662503. Epub 2016 Aug 10.
A workgroup of clinical experts has developed an Appropriate Use Criteria (AUC) for the use of hyaluronic acid (HA) in the treatment of osteoarthritis (OA) of the knee. The increasingly broad and varied use of HA injections, lack of published clinical guidance, and limited coverage for their use has created the imperative to establish appropriateness criteria.
The experts of this workgroup represent rheumatology, orthopedic surgery, physiatry, sports medicine, and nursing clinicians with substantive knowledge of intra-articular HA therapy. This workgroup utilized the results of a systematic review of evidence, expert clinical opinion, and current evidence-based clinical practice guidelines to develop appropriateness criteria for the use of intra-articular HA for knee OA in 17 real-world clinical scenarios.
The workgroup scored the appropriateness of treatment of each patient scenario using a 9-point scale to designate a treatment as appropriate (7-9), uncertain (4-6), or inappropriate (1-3). Six scenarios were scored as appropriate, 10 scenarios were scored as uncertain, and 1 scenario was scored as inappropriate.
This article can assist clinicians in shared decision-making by providing best practices in considering HA injections for knee OA treatment. Moreover, this AUC article can aid payers and policy makers in determining reimbursement and preauthorization policies and more appropriately managing health care resources. It is clear that further research is still necessary-particularly in patient populations differentiated by OA severity-that may benefit the greatest from the use of HA injections for the treatment of knee OA.
一个临床专家工作组制定了透明质酸(HA)用于治疗膝关节骨关节炎(OA)的合理使用标准(AUC)。HA注射剂的使用日益广泛且多样,缺乏已发表的临床指南,以及其使用的保险覆盖范围有限,使得制定适当性标准变得势在必行。
该工作组的专家代表了对关节内HA治疗有深入了解的风湿病学、骨外科、物理医学与康复、运动医学和护理临床医生。该工作组利用系统证据综述结果、专家临床意见和当前基于证据的临床实践指南,为17种实际临床场景中关节内HA用于膝关节OA制定了适当性标准。
工作组使用9分制对每个患者场景的治疗适当性进行评分,将治疗指定为适当(7 - 9分)、不确定(4 - 6分)或不适当(1 - 3分)。六个场景被评为适当,十个场景被评为不确定,一个场景被评为不适当。
本文可通过提供考虑HA注射治疗膝关节OA的最佳实践,协助临床医生进行共同决策。此外,这篇AUC文章可帮助支付方和政策制定者确定报销和预先授权政策,并更合理地管理医疗资源。显然,仍有必要进行进一步研究——特别是在根据OA严重程度区分的患者群体中——这些患者可能从使用HA注射治疗膝关节OA中获益最大。